aap Implantate AG /
aap Implantate AG launches new company website
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) today announced the launch of a new company
website. The website can be accessed at www.aap.de.
The updated website includes a streamlined user-interface and is designed to be
more user-friendly. It includes all of the essential company information for
customers, investors and potential shareholders. The main focus of the website
is in the Investors and Products sections. In the products section, all of aap's
Trauma and Biomaterials products are presented along with their specific
characteristics and advantages. For LOQTEQÂ®, a special navigation aid, the
"LOQTEQÂ®-man", was created to educate visitors on this innovative line of trauma
products. In the Investors section, standard company information is presented,
including the aap's annual and quarterly financial statements, real-time stock
price information and key indicators, press releases and ad hoc announcements,
presentations, analyses, the financial calendar as well as items concerning the
annual general meeting and corporate governance.
The website is available in two languages, German and English, with plans to
additional language options as the Company continues to build its presence in
Biense Visser, CEO of aap Implantate AG: "Over the last few years, we have
successfully focused aap's business on the Company's core competencies in trauma
products and biomaterials, while also driving growth in international markets.
The launch of our updated corporate website reflects our excellent progress with
these initiatives and aap's enhanced position in the market. The new website is
easy to navigate and provides a clear overview of the Company, which is
important as we secure interest from potential customers, partners and investors
around the world."
This release contains forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a global medical device company headquartered in Berlin, Germany that
develops, manufactures and markets innovative biomaterials and implants that are
used in orthopedic procedures. The Company's products, which include a full line
of plating systems, cannulated screws and bone cement products, are primarily
used in the orthopedic specialty areas of trauma and spine repair. The Company's
products are sold through its direct sales force, distribution partners and
license agreements with OEM partners. aap's stock is listed in the Prime
Standard segment of the Frankfurt Stock Exchange. For more information, please
visit www.aap.de, or download the Company's investor relations app from the
Apple's App Store or Google Play.
For inquiries please contact:
aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin,
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, email@example.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE